Can a diabetes drug shield the heart before failure strikes?

NCT ID NCT06507657

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether empagliflozin, a drug originally for diabetes, can improve left atrial function in 80 adults over 60 with hypertension and obesity who are at risk for heart failure. Participants take either a 10 mg empagliflozin tablet or a placebo daily for 9 months. The goal is to see if the drug helps the heart's upper chambers work better, potentially preventing future heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin
What this could lead to: If it works, this could point toward a way to prevent heart failure in people with high blood pressure and obesity.
What could go wrong: This is a very early, small pilot study with only 80 participants. It may not show clear benefits, and empagliflozin can cause side effects like dehydration or urinary infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder hypertensive disorder heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES HYPERTENSION

Contacts and locations

Locations

University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.